Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Investing.com -- 艾沙株式会社 (Eisai Co.)股价当日上涨0.4%，此前一度下跌，投资者正在消化该公司季度业绩报告，报告显示其阿尔茨海默病药物乐伐替尼 (Leqembi)销售强劲增长。 这家日本制药公司报告称，第一季度乐伐替尼全球销售额同比增长269%，达到¥23.1亿。然而，这一令人印象深刻的增长包括来自中国的¥5.3亿一次性需求，这一点此前已在合作伙伴Biogen ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment.

Biogen Inc <BIIB.O> revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed ...

Quiver AI Summary Eisai Co., Ltd. and Biogen Inc. have provided an update on the regulatory review of their Alzheimer’s disease treatment, lecanemab, in the European Union.